Oppenheimer analyst Kevin DeGeeter lowered the price target on Taysha Gene Therapies (NASDAQ: TSHA) to $37.00 (from $45.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE